PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

D & M Company Co., Ltd.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (13)

D & M Company Co., Ltd. owes ¥0.80 for every ¥1 it owns. Net profit rose 1% in the year to May 2026, and grew 9% a year on average over 3 years.

Compared with Healthcare companies in Japan · latest annual results May 2026.

P/E ratio

11.4

Investors pay ¥11.4 for every ¥1 of D & M Company Co., Ltd.'s yearly profit, lower than 75% of Healthcare companies in Japan.

P/B ratio

1.04

The share price is 1.04 times D & M Company Co., Ltd.'s book value per share, lower than 74% of Healthcare companies in Japan.

Market cap

¥2.5 B

The total market value of all of D & M Company Co., Ltd.'s shares at today's price (share price × number of shares), smaller than 94% of Healthcare companies in Japan. PosiCap size class: Micro Cap.

Net worth (book value)

¥2.4 B

What D & M Company Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Aug 2026).

Book value per share

¥1,027

Net worth divided by the number of shares. The share price of ¥1,067 is 1.0 times this, which is the P/B above.

Return on equity (ROE)

10.6%

D & M Company Co., Ltd. earned 10.6% on its shareholders' money over the last year, higher than 67% of Healthcare companies in Japan.

Owes vs Owns

0.80×

D & M Company Co., Ltd. owes ¥0.80 for every ¥1 it owns (moderate), higher than 91% of Healthcare companies in Japan.

Dividend yield

1.87%

D & M Company Co., Ltd. pays 1.87% of its share price as dividends a year, lower than 73% of dividend-paying Healthcare companies in Japan.

Revenue growth

+8%

Revenue rose 8% in the year to May 2026, and grew 13% a year on average over 3 years.

Profit growth

+1%

Net profit rose 1% in the year to May 2026, and grew 9% a year on average over 3 years.

Profit margin

13.7%

D & M Company Co., Ltd. keeps ¥14 of every ¥100 of revenue as net profit.

Cash quality

-3.6×

Cash from D & M Company Co., Ltd.'s business was -3.6× its reported profit in the year to May 2026 — the business used cash even though it reported a profit.

Cash vs debt

Net debt

D & M Company Co., Ltd. had ¥7.4 B more debt than cash (net debt) at May 2026.

Questions

What is D & M Company Co., Ltd.'s P/E ratio?

Investors pay ¥11.4 for every ¥1 of D & M Company Co., Ltd.'s yearly profit, lower than 75% of Healthcare companies in Japan.

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For D & M Company Co., Ltd.: ¥2.5 B ÷ ¥2.4 B (31 Aug 2026) = 1.0.

What is D & M Company Co., Ltd.'s return on equity?

D & M Company Co., Ltd. earned 10.6% on its shareholders' money over the last year, higher than 67% of Healthcare companies in Japan.

How much does D & M Company Co., Ltd. owe compared with what it owns?

D & M Company Co., Ltd. owes ¥0.80 for every ¥1 it owns (moderate), higher than 91% of Healthcare companies in Japan.

Does D & M Company Co., Ltd. pay a dividend?

Yes. D & M Company Co., Ltd. pays 1.87% of its share price as dividends a year, lower than 73% of dividend-paying Healthcare companies in Japan.

Is D & M Company Co., Ltd.'s revenue growing?

Revenue rose 8% in the year to May 2026, and grew 13% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.